| Identification | Back Directory | [Name]
GANAXOLONE | [CAS]
38398-32-2 | [Synonyms]
3α-hydroxy-3β-methyl-5α-pregnan-20-one
(3α,5α)-3-Hydroxy-3-methyl-pregnan-20-one
1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-Hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone | [Molecular Formula]
C22H36O2 | [MDL Number]
MFCD00945298 | [MOL File]
38398-32-2.mol | [Molecular Weight]
332.52 |
| Chemical Properties | Back Directory | [Melting point ]
190-192° | [alpha ]
D +103° | [Boiling point ]
434.8±18.0 °C(Predicted) | [density ]
1.036±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ~4.2 mg/mL
| [form ]
solid
| [pka]
15.18±0.70(Predicted) | [color ]
white
|
| Hazard Information | Back Directory | [Description]
Ganaxolone is a 3β-methylated synthetic analog of the neurosteroid allopregnanolone that allosterically enhances GABAA receptor current.1,2 At nanomolar concentrations, it can potentiate GABA-evoked currents at GABAA receptor complexes containing α1, α2, α3, β2, and γ2L subunits expressed in Xenopus oocytes.1,2 Ganaxolone has been shown to have a broad range of antiseizure activity in animal epilepsy models and human clinical trials.3,4,5 | [Uses]
Treatment of epilepsy and migraine. | [Definition]
ChEBI: Ganaxolone is a corticosteroid hormone. | [Biological Activity]
Potent positive allosteric modulator of GABA A receptors. Enhances GABA-evoked chloride currents in Xenopus oocytes expressing GABA A receptors (EC 50 values are 94, 122 and 213 nM for α 2 β 1 γ 2 L , α 3 β 1 γ 2 L and α 1 β 1 γ 2 L receptors respectively). Exerts anticonvulsive effects in a broad range of animal seizure models. | [Biochem/physiol Actions]
Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnane-20-one) is a positive allosteric modulator of the GABAA receptor subtype; synthetic analog of the endogenous neurosteroid allopregnanolone; effective against chemically induced seizures in rats and mice. Ganaxolone is an orally active analog of allopregnanolone that is not converted to the hormonally active 3-keto form. The enhanced anticonvulsant potency of ganaxolone after neurosteroid withdrawal supports the use of ganaxolone as a specific treatment for perimenstrual catamenial epilepsy. | [storage]
+4°C |
|
|